Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review

Cortese, 2019, Pembrolizumab treatment for progressive multifocal leukoencephalopathy, New Engl J Med, 380, 1597, 10.1056/NEJMoa1815039 Bohra, 2017, Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review, Cancer Control, 24, 10.1177/1073274817729901 Darcy, 2021, Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases, J Neurovirol Möhn, 2021, PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy, Ther Adv Neurol Disord, 14, 10.1177/1756286421993684 Volk, 2021, Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients [published online ahead of print, 2021 Jul 1], J Neurol, 10 Focosi, 2019, Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab, Rev Med Virol, 29, 10.1002/rmv.2077 Holmes, 2020, Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab, J Neurovirol, 26, 961, 10.1007/s13365-020-00899-0 Tan, 2012, Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy, J Acquir Immune Defic Syndr, 60, 244, 10.1097/QAI.0b013e31825a313c Grabmeier-Pfstershammer, 2011, Identifcation of PD-1as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment, J Acquir Immune Defic Syndr, 56, 118, 10.1097/QAI.0b013e3181fbab9f Küpper, 2019, Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency, Neurol Neuroimmunol Neuroinflamm, 6, 10.1212/NXI.0000000000000628 Rauer, 2019, Treatment of progressive multifocal leukoencephalopathy with pembrolizumab, New Engl J Med, 380, 1676, 10.1056/NEJMc1817193 M. Mozo Ruiz, N. Rosado Barrasa, D. Tena Gómez, M. Torralba González de Suso, Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with Human Immunodeficiency Virus infection Trat con pembrolizumab En Paciente con Infecc por Virus De la inmunodeficiencia Hum Y leucoencefalopatía multifocal Progres Enferm Infecc Microbiol Clin (Engl Ed), 38, 8, 2020, pp. 396–397 doi: 10.1016/j.eimc.2019.12.008. Pawlitzki, 2019, Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?, Neurol Neuroimmunol Neuroinflamm, 6, 10.1212/NXI.0000000000000627 Kapadia, 2020, Stabilization of progressive multifocal leukoencephalopathy after pembrolizumab treatment, Neurohospitalist, 10, 238, 10.1177/1941874420902872 Mahler, 2020, Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy, Neurol Neuroimmunol Neuroinflamm, 7, 10.1212/NXI.0000000000000756 Goereci, 2020, Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome, Eur J Neurol, 27, 2375, 10.1111/ene.14435 Stögbauer, 2021, Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report, Neurol Sci, 42, 357, 10.1007/s10072-020-04582-4